gallium 68 PSMA-11

For detection and localization of prostate cancer.

Also Known As:

(68)Ga-PSMA; (68Ga)Glu-urea-Lys(Ahx)-HBED-CC; 68 Ga-PSMA-I and T; 68 Ga-PSMA-I-T; 68Ga-PSMA; 68Ga-PSMA-11; GA-68 PSMA-11; Glu-NH-CO-NH-Lys-(Ahx)-((68)Ga(HBED-CC)); Glu-NH-CO-NH-Lys-(Ahx)-(68Ga(HBED-CC)); PSMA-HBED-CC Ga-68; gallium GA-68 gozetotide

Networked: 745 relevant articles (33 outcomes, 117 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Eiber, Matthias: 44 articles (01/2022 - 08/2015)
2.	Haberkorn, Uwe: 29 articles (04/2020 - 10/2013)
3.	Fendler, Wolfgang P: 23 articles (11/2022 - 06/2016)
4.	Calais, Jeremie: 21 articles (01/2022 - 10/2017)
5.	Afshar-Oromieh, Ali: 21 articles (01/2021 - 10/2013)
6.	Herrmann, Ken: 20 articles (01/2022 - 06/2015)
7.	Hope, Thomas A: 19 articles (11/2022 - 01/2017)
8.	Fanti, Stefano: 19 articles (01/2022 - 07/2015)
9.	Maurer, Tobias: 19 articles (12/2021 - 08/2015)
10.	Ceci, Francesco: 19 articles (11/2021 - 07/2015)

Related Diseases

1.	Prostatic Neoplasms (Prostate Cancer) 02/21/2023 - "Detection Efficacy of 68Ga-PSMA-11 PET/CT in Biochemical Recurrence of Prostate Cancer with Very Low PSA Levels: A 7-Year, Two-Center "Real-World" Experience." 01/01/2021 - "This study aimed to evaluate the efficacy of 68Ga-PSMA-11 PET/CT as a triage tool for prostate biopsy (PSMA-TB) and compare with transrectal ultrasound-guided biopsy (TRUS-GB) for the diagnosis of clinically significant prostate cancer (csPCa). " 07/01/2022 - "We aimed to evaluate whether pretreatment 68Ga-PSMA PET/CT is beneficial for identifying pathological lymph node involvement (LNI) and adverse pathology among patients with favorable intermediate-risk prostate cancer. " 01/01/2022 - "This retrospective study aimed to investigate the efficacy of the combined application of biparametric magnetic resonance imaging (bpMRI) and 68Ga-PSMA-11 positron emission computed tomography/computed tomography (bpMRI/PET) in the qualitative diagnosis of intermediate- to high-risk prostate cancer (PCa). " 09/09/2017 - "68Ga-PSMA offers significant promise for both, primary disease and biochemically recurrent prostate cancer. "
2.	Neoplasm Metastasis (Metastasis) 10/01/2018 - "68Ga-PSMA PET/CT is superior to and can potentially replace bone scan in the evaluation for skeletal metastases in the clinical and trial setting because of its ability to detect lytic and bone marrow metastases." 02/14/2017 - "68Ga-PSMA-11 PET/CT exhibits potential for staging and risk stratification in naïve PCa, as well as improved sensitivity for detection of lymph node and remote metastasis." 01/01/2021 - "This analysis did not show an improvement in BRFS using 68Ga-PSMA PET/CT prior to sRT neither for the entire cohort nor after matched-pair analysis after excluding patients with PET-positive lymph node or distant metastases a priori. " 01/01/2021 - "Given the majority of metastasis constituted unexpected findings on routine restaging 68Ga-PSMA PET/CT, the incidence determined in our study is arguably the most accurate and clinically relevant described to date." 01/01/2019 - "In two of the study patients 68Ga-PSMA PET-CT identified unexpected extrahepatic metastases. "
3.	Neoplasms (Cancer) 10/05/2021 - "Furthermore, compared to the clinically used monomeric PSMA-targeting tracers, 68Ga-PSMA-11 and 18F-PSMA-1007, 18F-Bi-PSMA exhibited improved pharmacokinetics and higher tumor uptake, as well as better tumor-to-normal tissue contrast, resulting in considerably high imaging quality. " 04/01/2019 - "In addition, the risk of PCa was positively correlated with a higher SUVmax and lower prostate volume, which could help clinicians in making preliminary estimates of individual cancer risk, monitoring 68Ga-PSMA PET/CT false-positive results and making biopsy decisions in daily medical practice." 10/01/2018 - "68Ga-PSMA-11 PET/CT-derived metabolic tumor parameters showed promising results for evaluation of treatment response. " 11/01/2022 - "In this study, 68Ga-PSMA PET/CT (PSMA) and multiparametric prostate MRI (mp-MRI) were compared in regard to locating intraprostatic tumor and locoregional staging. " 10/01/2022 - "Recent studies have focused on the role of 68Ga-PSMA PET in imaging of glial tumors. "
4.	Pyelonephritis 03/01/2021 - "Conclusion: In our first case, 68Ga-PSMA-11 PET imaging provided promising results in an adult patient with pyelonephritis. " 03/01/2021 - "The results of our prospective study on a larger number of adult patients will provide a more accurate comparison of 68Ga-PSMA-11 PET to 99mTc-DMSA scanning in pyelonephritis." 03/01/2022 - "Here, we present the renal cortical 68Ga-PSMA-11 PET and 99mTc-DMSA images of our second patient, who had chronic recurring pyelonephritis and demonstrated renal parenchymal defects secondary to scarring in the kidney." 03/01/2022 - "Renal Cortical Scarring: 68Ga-PSMA-11 PET Versus 99mTc-DMSA Scanning in a Case of Pyelonephritis." 03/01/2021 - "We recently started a prospective research study to compare 68Ga-PSMA-11 PET/CT with 99mTc-dimercaptosuccinic acid (DMSA) scan in adults with pyelonephritis. "
5.	Hepatocellular Carcinoma (Hepatoma) 01/01/2019 - "68Ga-PSMA is a novel PET-CT tracer for imaging of hepatocellular carcinoma: A prospective pilot study." 01/01/2017 - "68Ga-PSMA Uptake in Hepatocellular Carcinoma." 04/01/2016 - "(68)Ga-PSMA PET/CT imaging in primary hepatocellular carcinoma." 11/06/2023 - "PSMA expression is seen in many solid tumours in addition to prostate cancer and several studies and case reports have shown PSMA expression and 68Ga-PSMA imaging of hepatocellular carcinoma (HCC). " 01/01/2021 - "68Ga-PSMA-11 PET/CT Improves Tumor Detection and Impacts Management in Patients with Hepatocellular Carcinoma."

Related Drugs and Biologics

1.	Ligands
2.	Antigens
3.	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)
4.	Biomarkers (Surrogate Marker)
5.	Hormones (Hormone)
6.	Technetium Tc 99m Medronate
7.	Androgen Receptors (Androgen Receptor)
8.	Glutamic Acid (Glutamate)
9.	Histidine (L-Histidine)
10.	Prostate-Specific Antigen (Semenogelase)

Related Therapies and Procedures

1.	Radiotherapy
2.	Therapeutics
3.	Prostatectomy (Retropubic Prostatectomy)
4.	Castration
5.	Re-Irradiation